Glutamine stimulates the S6K/4E-BP branch of insulin signalling pathway to mitigate human poly(Q) disorders in Drosophila disease models

References

• Silva A, de Almeida AV, Macedo-Ribeiro S. Polyglutamine expansion diseases: more than simple repeats. J Struct Biol. 2018;201:139–54. doi:10.1016/j.jsb.2017.09.006
   PubMed Web of Science ®Google Scholar
• Bunting EL, Hamilton J, Tabrizi SJ. Polyglutamine diseases. Curr Opin Neurobiol. 2022;72:39–47. doi:10.1016/j.conb.2021.07.001
   PubMed Web of Science ®Google Scholar
• Lieberman AP, Shakkottai VG, Albin RL. Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol. 2019;14:1–27. doi:10.1146/annurev-pathmechdis-012418-012857
   PubMed Web of Science ®Google Scholar
• Raj K, Sarkar S. Tissue-specific upregulation of Drosophila insulin receptor (InR) mitigates poly(Q)-mediated neurotoxicity by restoration of cellular transcription machinery. Mol Neurobiol. 2019;56:1310–29. doi:10.1007/s12035-018-1160-3
   PubMed Web of Science ®Google Scholar
• Tandon S, Sarkar S. The S6k/4E-BP mediated growth promoting sub-pathway of insulin signalling cascade is essential to restrict pathogenesis of poly(Q) disorders in Drosophila. Life Sci. 2021;275:119358. doi:10.1016/j.lfs.2021.119358
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Cremona ML, Rothman JE. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol. 2006;172:719–31. doi:10.1083/jcb.200510065
   PubMed Web of Science ®Google Scholar
• Deldicque L, Sanchez Canedo C, Horman S, De Potter I, Bertrand L, Hue L, et al. Antagonistic effects of leucine and glutamine on the mTOR pathway in myogenic C2C12 cells. Amino Acids. 2008;35:147–55. doi:10.1007/s00726-007-0607-z
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169:361–71. doi:10.1016/j.cell.2017.03.035
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhang W, Zhou Y, Li F, Wei H, Peng J. Recent advances in understanding amino acid sensing mechanisms that regulate mTORC1. Int J Mol Sci. 2016;17:1636. doi:10.3390/ijms17101636
   PubMed Web of Science ®Google Scholar
• Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15:155–62. doi:10.1038/nrm3757
   PubMed Web of Science ®Google Scholar
• Rhoads J M, Wu G. Glutamine, arginine, and leucine signaling in the intestine. Amino Acids. 2009;37:111–22. doi:10.1007/s00726-008-0225-4
   PubMed Web of Science ®Google Scholar
• Fumarola C, La Monica S, Guidotti GG. Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: role of glutamine and of cell shrinkage. J Cell Physiol. 2005;204:155–65. doi:10.1002/jcp.20272
   PubMed Web of Science ®Google Scholar
• Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10:1564. doi:10.3390/nu10111564
   PubMed Web of Science ®Google Scholar
• Kim H. Glutamine as an immunonutrient. Yonsei Med J. 2011;52:892–7. doi:10.3349/ymj.2011.52.6.892
   PubMed Web of Science ®Google Scholar
• Freeman M. Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye. Cell. 1996;87:651–60. doi:10.1016/S0092-8674(00)81385-9
   PubMed Web of Science ®Google Scholar
• Luo L, Liao YJ, Jan LY, Jan YN. Distinct morphogenetic functions of similar small GTPases: Drosophila Drac1 is involved in axonal outgrowth and myoblast fusion. Genes Dev. 1994;8:1787–802. doi:10.1101/gad.8.15.1787
   PubMed Web of Science ®Google Scholar
• Bonini NM. A genetic model for human polyglutamine-repeat disease in Drosophila melanogaster. Philos Trans R Soc Lond B Biol Sci. 1999;354:1057–60. doi:10.1098/rstb.1999.0458
   PubMed Web of Science ®Google Scholar
• Weiss KR, Kimura Y, Lee WC, Littleton JT. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Genetics. 2012;190:581–600. doi:10.1534/genetics.111.133710
   PubMed Web of Science ®Google Scholar
• Pierzyńska-Mach A, Janowski PA, Dobrucki JW. Evaluation of acridine orange, LysoTracker Red, and quinacrine as fluorescent probes for long-term tracking of acidic vesicles. Cytometry A. 2014;85:729–37. doi:10.1002/cyto.a.22495
   PubMedGoogle Scholar
• Shaw E, Talwadekar M, Rashida Z, Mohan N, Acharya A, Khatri S, et al. Anabolic SIRT4 exerts retrograde control over TORC1 signaling by glutamine sparing in the mitochondria. Mol Cell Biol. 2020;40:e00212–19. doi:10.1128/MCB.00212-19
   PubMed Web of Science ®Google Scholar
• Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Plouffe SW, et al. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Science. 2015;347:194–8. doi:10.1126/science.1259472
   PubMed Web of Science ®Google Scholar
• Tandon S, Sarkar S. Glipizide ameliorates human poly(Q) mediated neurotoxicity by upregulating insulin signalling in Drosophila disease models. Biochem Biophys Res Commun. 2023;645:88–96. doi:10.1016/j.bbrc.2023.01.022
   PubMed Web of Science ®Google Scholar
• Chen J, Herrup K. Glutamine acts as a neuroprotectant against DNA damage, beta-amyloid and H2O2-induced stress. PLoS One. 2012;7:e33177. doi:10.1371/journal.pone.0033177
   PubMed Web of Science ®Google Scholar
• Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell. 1998;93:939–49. doi:10.1016/S0092-8674(00)81200-3
   PubMed Web of Science ®Google Scholar
• Jafari-Vayghan H, Varshosaz P, Hajizadeh-Sharafabad F, Razmi HR, Amirpour M, Tavakoli-Rouzbehani OM, et al. A comprehensive insight into the effect of glutamine supplementation on metabolic variables in diabetes mellitus: a systematic review. Nutr Metab (Lond). 2020;17:80. doi:10.1186/s12986-020-00503-6
   PubMed Web of Science ®Google Scholar
• Skotte NH, Pouladi MA, Ehrnhoefer DE, Huynh K, Qiu X, Nielsen SMB, et al. Compromised IGF signaling causes caspase-6 activation in Huntington disease. Exp Neurol. 2020;332:113396. doi:10.1016/j.expneurol.2020.113396
   PubMed Web of Science ®Google Scholar
• Akhtar A, Sah SP. Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer's disease. Neurochem Int. 2020;135:104707. doi:10.1016/j.neuint.2020.104707
   PubMed Web of Science ®Google Scholar
• García-Huerta P, Troncoso-Escudero P, Wu D, Thiruvalluvan A, Cisternas-Olmedo M, Henríquez DR, et al. Insulin-like growth factor 2 (IGF2) protects against Huntington's disease through the extracellular disposal of protein aggregates. Acta Neuropathol. 2020;140:737–64. doi:10.1007/s00401-020-02183-1
   PubMed Web of Science ®Google Scholar
• Pennuto M, Pandey UB, Polanco MJ. Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: from molecular pathogenesis to therapeutic perspectives. Front Neuroendocrinol. 2020;57:100821. doi:10.1016/j.yfrne.2020.100821
   PubMed Web of Science ®Google Scholar
• Lenders CM, Liu S, Wilmore DW, Sampson L, Dougherty LW, Spiegelman D, et al. Evaluation of a novel food composition database that includes glutamine and other amino acids derived from gene sequencing data. Eur J Clin Nutr. 2009;63:1433–9. doi:10.1038/ejcn.2009.110
   PubMed Web of Science ®Google Scholar
• Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19:274. doi:10.1186/s13054-015-0993-7
   PubMed Web of Science ®Google Scholar
• Wischmeyer PE. Glutamine: role in critical illness and ongoing clinical trials. Curr Opin Gastroenterol. 2008;24:190–7. doi:10.1097/MOG.0b013e3282f4db94
   PubMed Web of Science ®Google Scholar
• Luo LL, Li YF, Shan HM, Wang LP, Yuan F, Ma YY, et al. L-glutamine protects mouse brain from ischemic injury via up-regulating heat shock protein 70. CNS Neurosci Ther. 2019;25:1030–41. doi:10.1111/cns.13184
   PubMed Web of Science ®Google Scholar
• Quinn CT. l-Glutamine for sickle cell anemia: more questions than answers. Blood. 2018;132:689–93. doi:10.1182/blood-2018-03-834440
   PubMed Web of Science ®Google Scholar
• Chen J, Chen Y, Vail G, Chow H, Zhang Y, Louie L, et al. The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: a preclinical assessment. Mol Neurodegener. 2016;11:60. doi:10.1186/s13024-016-0127-y
   PubMed Web of Science ®Google Scholar
• Rozas NS, Redell JB, McKenna J3, Moore AN, Gambello MJ, Dash PK. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation. Biochem Biophys Res Commun. 2015;457:635–9. doi:10.1016/j.bbrc.2015.01.039
   PubMed Web of Science ®Google Scholar
• Kimball SR, Jefferson LS. New functions for amino acids: effects on gene transcription and translation. Am J Clin Nutr. 2006;83:500S–507S. doi:10.1093/ajcn/83.2.500S
   PubMed Web of Science ®Google Scholar
• Xia Y, Wen HY, Young ME, Guthrie PH, Taegtmeyer H, Kellems RE. Mammalian target of rapamycin and protein kinase A signaling mediate the cardiac transcriptional response to glutamine. J Biol Chem. 2003;278:13143–50. doi:10.1074/jbc.M208500200
   PubMed Web of Science ®Google Scholar
• Højfeldt JW, Hulin K. Regional tumour glutamine supply affects chromatin and cell identity. Nat Cell Biol. 2016;18:1027–9. doi:10.1038/ncb3414
   PubMed Web of Science ®Google Scholar